CSC Finds Majority of World’s Largest Companies Susceptible to Phishing and Brand Abuse Due to Improper Domain Security
28.9.2021 16:00:00 EEST | Business Wire | Press release
CSC, a world leader in business, legal, tax, and domain security, today released its annual Domain Security Report: Forbes Global 2000 Companies , which found that despite the shift to modernize business environments and operations among the Global 2000 companies, web domains remain dangerously under protected.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928005027/en/
Key findings from the 2021 Domain Security Report (Graphic: Business Wire)
CSC’s research also shows that most Global 2000 companies continue to lag in the adoption of domain security measures. Most notably, 81% of companies are not using registry locks. Other concerning findings illustrate that domain security remains an afterthought for many brands:
- 70% of homoglyph (fuzzy match) domains—a tactic commonly used in phishing and brand abuse—are owned by third parties
- 57% of the Global 2000 are relying on off-the-shelf consumer-grade registrars who offer limited domain security mechanisms to protect against domain and DNS hijacking
“Basic domain security measures continue to get overlooked because they’re still not considered an essential component to a company’s broader phishing, business email compromise, or ransomware mitigation approach,” said Mark Calandra, president of CSC Digital Brand Services. “A focus on securing legitimate domains while monitoring for malicious domains in parallel needs to be a bigger priority for companies to stay protected and thwart cyber risk. Otherwise, companies are exposing themselves to significant threats to their cyber security posture, data protection, intellectual property, supply chains, consumer safety, revenue, and reputation.”
CSC’s additional findings leave little doubt that bad actors are applying tactics to hide their tracks and accelerate their attempts to execute their attacks. The research found that among the 70% of third-party domains deemed suspicious:
- 77% used domain privacy services or also had WHOIS details redacted
- 43% are configured with MX email records, giving them the ability to send phishing emails
- 56% were pointing to advertising, pay-per-click content, or being used for domain parking
- 38% had inactive web content
- 6% were pointing to brand impersonation and malicious content including phishing and potential malware delivery
The rise of cyber crime and digital fraud, along with a steady increase in domain registrations over the last 18 months, necessitates more industry oversight. At the same time, it’s imperative that companies get proactive with their domain security moving forward. Including security measures can help mitigate phishing—a common starting point in most ransomware attacks. Companies need to take a more aggressive cyber security approach to disrupt criminal activities taking place across their domain ecosystem.
Download the report now at cscdbs.com/securityreport .
To learn more about CSC’s approach to domain security, visit cscdbs.com.
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® for enterprise domain names, domain name system, and digital certificate management, as well as digital brand, fraud, and phishing protection. We secure companies against cyber threats to their online assets using our proprietary security solutions, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties. We also provide a combination of online brand monitoring and enforcement, taking a holistic approach to digital asset protection. Learn more about our domain management, security, brand protection, and fraud protection services at cscdbs.com.
Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005027/en/
Contact information
Steve Bosk
W2 Communications
215-378-1056
CSC@w2comm.com
CSC Newsroom
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
